source
- Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefitMirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage s…
- Asahi Kasei Therapeutics receives FDA approval for HSV drug acquired in $1 billion dealAsahi Kasei Therapeutics announced that the U.S. Food and Drug Administration granted approval for its herpes simplex virus (HSV) therapy. The drug, called Hovilpri, was purchased by Asahi Kasei e…